An official website of the United States government
A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
Trial Status: complete
The purpose of this study is to evaluate the safety, recommended dose, and preliminary
anti-tumor activity of WU-CART-007 in patients with relapsed or refractory (R/R) T-cell
acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL).
Inclusion Criteria
Key Eligibility Criteria:
- Diagnosed relapsed or refractory T-ALL or T-LBL, as defined by World Health
Organization (WHO) classification
- Adequate renal, hepatic, respiratory, and cardiovascular function
- Life expectancy >12 weeks
- ECOG/Karnofsky performance status 0 or 1 at screening (Adults age >16) or Lansky
Performance Status 60 and above (adolescents ≤ 16),
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04984356.
Locations matching your search criteria
United States
California
Los Angeles
Children's Hospital Los Angeles
Status: Active
Name Not Available
Pennsylvania
Philadelphia
Children's Hospital of Philadelphia
Status: Active
Name Not Available
This is a first-in-human, multicenter, Phase 1, single-arm study in patients with R/R
T-ALL/T-LBL who have exhausted other treatment options. The study evaluates dose
escalation and dose expansion.
Trial PhasePhase I
Trial Typetreatment
Lead OrganizationWugen, Inc.
Primary IDWU-CART-007 1001
Secondary IDsNCI-2022-01124, R35CA210084, Wugen, Inc. is the sponsor.
